Shanghai, China

Haiying He

USPTO Granted Patents = 52 

 

Average Co-Inventor Count = 6.2

ph-index = 4

Forward Citations = 82(Granted Patents)


Location History:

  • Jiangsu, CN (2018)
  • Lianyungang, CN (2019)
  • Nanjing, CN (2021 - 2022)
  • Shanghai, CN (2013 - 2024)

Company Filing History:

goldMedal8 out of 118 
 
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
 patents
silverMedal8 out of 65 
 
Medshine Discovery Inc.
 patents
bronzeMedal6 out of 10 
 
Shandong Danhong Pharmaceutical Co., Ltd.
 patents
45 out of 20 
 
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
 patents
55 out of 26 
 
Yangtze River Pharmaceutical Group Co., Ltd.
 patents
64 out of 8 
 
Zhuhai United Laboratories Co., Ltd.
 patents
72 out of 11 
 
Qilu Pharmaceutical Co., Ltd.
 patents
82 out of 13 
 
Guangdong Raynovent Biotech Co., Ltd.
 patents
92 out of 31 
 
Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.
 patents
102 out of 2 
 
Heilongjiang Zhenbaodao Pharmaceutical Co, Ltd
 patents
112 out of 16 
 
Jiangsu Kanion Pharmaceutical Co., Ltd.
 patents
122 out of 3 
 
Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.
 patents
132 out of 7 
 
Fujian Akeylink Biotechnology Co., Ltd.
 patents
142 out of 14 
 
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.
 patents
152 out of 20 
 
Janssen Biopharma, Inc.
 patents
161 out of 44 
 
Alios Biopharma, Inc.
 patents
171 out of 4 
 
Zhongshan Ophthalmic Center, Sun Yat-sen University
 patents
181 out of 3 
 
Fujian Cosunter Pharmaceutical Co., Ltd.
 patents
191 out of 2 
 
Phaeno Therapeutics Co., Ltd.
 patents
201 out of 3,923 
 
Novartis Ag
 patents
211 out of 12 
 
Shanghai Allist Pharmaceuticals, Inc.
 patents
222 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...
Loading Chart...
52 patents (USPTO):

Title: The Innovative Contributions of Haiying He in Pharmaceutical Patents

Introduction: Haiying He, based in Shanghai, China, is a prominent inventor with a remarkable portfolio of 48 patents. His work significantly contributes to the field of pharmaceuticals, particularly in the development of new medications for various health conditions.

Latest Patents: Among his latest innovations are two notable patents. The first is titled "Solid form, crystalline form, and crystal form A of FXR agonist, and preparation method and application thereof." This patent discloses a solid form, a crystalline form, and a crystal form A of a specific compound used as an FXR agonist, along with its preparation method. The patent highlights the compound's application in developing medications for treating nonalcoholic steatohepatitis (NASH). The second patent focuses on a "Ring-modified proline short peptide compound and use thereof." This patent describes a ring-modified proline short peptide compound and its utilization, providing a compound represented by a specified formula or a pharmaceutically acceptable salt.

Career Highlights: Haiying He's professional journey includes significant roles at well-known pharmaceutical companies. He has worked with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Medshine Discovery Inc., where he contributed to various research and development projects that have advanced pharmaceutical innovation.

Collaborations: Throughout his career, He has collaborated with experts in the field, including notable coworkers such as Shuhui Chen and Zhigan Jiang. These collaborations have fostered an environment of shared knowledge and innovation that has benefitted their respective projects and the pharmaceutical industry as a whole.

Conclusion: Haiying He's dedication to pharmaceutical innovation is reflected in his impressive number of patents and the innovative solutions he has developed. His contributions, particularly concerning treatments for conditions like NASH, underscore the importance of continuous research and development in healthcare advancements. The future promises to hold even more impactful inventions from this talented inventor as he continues to push the boundaries of pharmaceutical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…